[Microwave heating and neoadjuvant chemotherapy for malignant bone tumor].
Neoadjuvant chemotherapy for peripheral malignant neuroectodermal tumor of bone: recent experience at the istituto rizzoli.
A report of renal artery embolization for hematuria facilitating neoadjuvant chemotherapy in an unresectable malignant renal rhabdoid tumor.
Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850).
Fagotti A, Ferrandina MG, Vizzielli G, Pasciuto T, Fanfani F, Gallotta V, Margariti PA, Chiantera V, Costantini B, Gueli Alletti S, Cosentino F, Scambia G.
Int J Gynecol Cancer. 2020 Nov;30(11):1657-1664. doi: 10.1136/ijgc-2020-001640. Epub 2020 Oct 7.
Biomarkers of neoadjuvant/adjuvant chemotherapy for breast cancer.
Iwamoto T, Kajiwara Y, Zhu Y, Iha S.
Chin Clin Oncol. 2020 Jun;9(3):27. doi: 10.21037/cco.2020.01.06. Epub 2020 Mar 13.
Neoadjuvant treatment for HER2-positive breast cancer.
Takada M, Toi M.
Chin Clin Oncol. 2020 Jun;9(3):32. doi: 10.21037/cco-20-123. Epub 2020 Jun 3.
Neoadjuvant or adjuvant chemotherapy in early breast cancer?
Montemurro F, Nuzzolese I, Ponzone R.
Expert Opin Pharmacother. 2020 Jun;21(9):1071-1082. doi: 10.1080/14656566.2020.1746273. Epub 2020 Apr 1.
Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups.
Gronchi A, Palmerini E, Quagliuolo V, Martin Broto J, Lopez Pousa A, Grignani G, Brunello A, Blay JY, Tendero O, Diaz Beveridge R, Ferraresi V, Lugowska I, Merlo DF, Fontana V, Marchesi E, Braglia L, Donati DM, Palassini E, Bianchi G, Marrari A, Morosi C, Stacchiotti S, Bagué S, Coindre JM, Dei Tos AP, Picci P, Bruzzi P, Casali PG.
J Clin Oncol. 2020 Jul 1;38(19):2178-2186. doi: 10.1200/JCO.19.03289. Epub 2020 May 18.
Effect of neoadjuvant chemotherapy on tumor immune infiltration in breast cancer patients: Systematic review and meta-analysis.
Llano-León M, Martínez-Enriquez LC, Rodríguez-Bohórquez OM, Velandia-Vargas EA, Lalinde-Ruíz N, Villota-Álava MA, Rodríguez-Rodríguez IJ, Montilla-Velásquez MDP, Parra-López CA.
PLoS One. 2023 Apr 27;18(4):e0277714. doi: 10.1371/journal.pone.0277714. eCollection 2023.
Evaluation of tumor regression by neoadjuvant chemotherapy regimens for esophageal adenocarcinoma: a systematic review and meta-analysis.
Chidambaram S, Sounderajah V, Maynard N, Owen R, Markar SR.
Dis Esophagus. 2023 Jan 28;36(2):doac058. doi: 10.1093/dote/doac058.
Two-year outcomes of clinical N2-3 esophageal squamous cell carcinoma after neoadjuvant chemotherapy and immunotherapy from the phase 2 NICE study.
Yang Y, Liu J, Liu Z, Zhu L, Chen H, Yu B, Zhang R, Shao J, Zhang M, Li C, Li Z.
J Thorac Cardiovasc Surg. 2024 Mar;167(3):838-847.e1. doi: 10.1016/j.jtcvs.2023.08.056. Epub 2023 Sep 9.
Safety of neoadjuvant chemotherapy for the treatment of breast cancer.
Ahmed SH.
Expert Opin Drug Saf. 2019 Sep;18(9):817-827. doi: 10.1080/14740338.2019.1644318. Epub 2019 Jul 22.
Monitoring of Triple Negative Breast Cancer After Neoadjuvant Chemotherapy.
Aldrich J, Canning M, Bhave M.
Clin Breast Cancer. 2023 Dec;23(8):832-834. doi: 10.1016/j.clbc.2023.08.001. Epub 2023 Aug 5.
